Financial Instruments and Fair Value Measurements (Tables)

9 Months Ended

Sep. 29, 2017

Schedule of Fair Value of Assets and Liabilities Measured on a Recurring Basis

The following tables provide a summary of the significant assets and liabilities that are measured at fair value on a recurring basis at the end of each period:



	September 29, 2017		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Debt and equity securities held in rabbi trusts	$	34.1	$	23.2	$	10.9	$	—
Equity securities	21.6		21.6		—		—
Foreign exchange forward and option contracts	0.6		0.6		—		—
	$	56.3	$	45.4	$	10.9	$	—

Liabilities:
Deferred compensation liabilities	$	38.9	$	—	$	38.9	$	—
Contingent consideration and acquired contingent liabilities	268.6		—		—		268.6
Foreign exchange forward and option contracts	1.2		1.2		—		—
	$	308.7	$	1.2	$	38.9	$	268.6



	December 30, 2016		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Debt and equity securities held in rabbi trusts	$	33.6	$	22.8	$	10.8	$	—
Foreign exchange forward and option contracts	0.7		0.7		—		—
	$	34.3	$	23.5	$	10.8	$	—

Liabilities:
Deferred compensation liabilities	$	32.5	$	—	$	32.5	$	—
Contingent consideration and acquired contingent liabilities	250.5		—		—		250.5
Foreign exchange forward and option contracts	3.4		3.4		—		—
	$	286.4	$	3.4	$	32.5	$	250.5

Schedule of Reconciliation of Changes in Fair Value of Contingent Liabilities

The following table provides a summary of the changes in the Company's contingent consideration and acquired contingent liabilities:



Balance at December 30, 2016	$	250.5
Acquisition date fair value of contingent consideration	35.0
Payments	(25.0		)
Accretion expense	4.0
Fair value adjustment	4.1
Balance at September 29, 2017	$	268.6

Schedule of Carrying Amount and Fair Value of Long-term Debt

The following table presents the carrying values and estimated fair values of the Company's long-term debt, excluding capital leases, as of the end of each period:



	September 29, 2017				December 30, 2016
	Carrying Value		Fair Value		Carrying Value		Fair Value
Variable-rate receivable securitization due July 2017	$	—	$	—	$	250.0	$	250.0
3.50% notes due April 2018	300.0		300.2		300.0		298.7
4.875% notes due April 2020	700.0		696.7		700.0		699.5
Variable-rate receivable securitization due July 2020	200.0		200.0		—		—
Term loans due March 2021	—		—		1,948.5		1,953.2
4.00% term loan due February 2022	—		—		6.5		6.5
9.50% debentures due May 2022	10.4		11.5		10.4		12.0
5.75% notes due August 2022	884.0		853.3		884.0		850.3
8.00% debentures due March 2023	4.4		4.7		4.4		4.9
4.75% notes due April 2023	526.5		448.5		600.0		520.9
5.625% notes due October 2023	738.0		689.5		738.0		682.4
Term loan due September 2024	1,855.7		1,853.8		—		—
5.50% notes due April 2025	692.1		625.4		695.0		615.7
Revolving credit facility	—		—		100.0		100.0

Schedules of Concentration of Risk

The following table shows net sales attributable to distributors that accounted for 10% or more of the Company's total net sales:



	Three Months Ended				Nine Months Ended
	September 29, 2017		September 30, 2016		September 29, 2017		September 30, 2016
CuraScript, Inc.	41	%	40	%	40	%	37	%
McKesson Corporation	9	%	11	%	9	%	11	%

The following table shows accounts receivable attributable to distributors that accounted for 10% or more of the Company's gross accounts receivable at the end of each period:



	September 29, 2017		December 30, 2016
McKesson Corporation	20	%	28	%
Amerisource Bergen Corporation	14	%	15	%
CuraScript, Inc.	14	%	15	%
Cardinal Health, Inc.	11	%	10	%

The following table shows net sales attributable to products that accounted for 10% or more of the Company's total net sales:



	Three Months Ended				Nine Months Ended
	September 29, 2017		September 30, 2016		September 29, 2017		September 30, 2016
Acthar	39	%	37	%	37	%	34	%
Inomax	16	%	14	%	16	%	14	%